Lillia, an AI-driven startup revolutionizing chronic care, has launched its platform designed to empower individuals living with diabetes and related chronic conditions to lead healthier and more fulfilling lives. By leveraging cutting-edge AI technology, Lillia aims to transform the management of chronic diseases, supporting healthcare providers, insurers, corporations, and public sector entities in the effective treatment of these conditions.
According to Sujit Chakrabarty, Lillia’s founder and CEO, “Diabetes and related chronic conditions are the world’s biggest healthcare challenge, impacting over 500 million people globally. The encouraging news is that with the right interventions, diabetes can be prevented, reversed in its early stages, or effectively managed to ensure long-term health.” Chakrabarty emphasized that Lillia’s mission is to reduce the global burden of chronic diseases by providing continuous, adaptive care that fosters meaningful, lasting lifestyle changes.
Lillia’s platform combines AI with expert human coaches, including psychologists, nutritionists, and doctors, to create a personalized care journey tailored to an individual’s unique metabolism and lifestyle. This innovative approach helps users develop sustainable microhabits that are supported by proven clinical outcomes. By using AI, the platform is able to adapt and guide users in real time, enabling them to make changes that promote long-term health and disease management.
The company’s vision was further unveiled at Web Summit Qatar, where it introduced the concept of a chronic care digital twin. This digital twin, paired with AI agents, brings predictive capabilities to the platform, offering real-time monitoring of health risks and enabling precision medication, among other applications. This new development is designed to enhance the platform’s ability to predict and manage chronic conditions with greater accuracy, providing more targeted and personalized care.
Lillia also announced that it has received a significant $1.7 million grant from the Qatar Research, Development and Innovation (QRDI) Council to develop the first digital twin for chronic conditions in the Gulf Cooperation Council (GCC) region. Nada Al-Olaqi, Director of Innovation Development and Piloting Programs at QRDI Council, expressed support for Lillia’s pioneering work: “We are proud to support Lillia as they push the boundaries of healthcare innovation through their AI-driven digital twin technology. Through our Technology Development Grant program, we empower forward-thinking companies like Lillia to bring transformative healthcare solutions to life. This collaboration is key to advancing healthcare, improving quality of life, and positioning Qatar as a global leader in digital transformation.”
Backed by major investors such as Qatar Development Bank, QSTP, and M Venture Partners, Lillia is scaling rapidly, with plans to expand across the MENA (Middle East and North Africa) and Southeast Asia regions in the next two years. Since its founding in 2020, Lillia has already supported over 40,000 individuals across the GCC and India, focusing on diabetes and weight-related conditions. The company works with 20 institutional clients across healthcare, corporate, insurance, and public sectors to deliver impressive, long-term clinical outcomes. Remarkably, up to 80% of patients enrolled in Lillia’s platform have achieved sustained health improvements.
Lillia’s innovative approach has garnered attention from key industry players. Mohammed Salem, Chief Business Officer of QLM Life and Medical Insurance, shared his enthusiasm for the company’s potential: “We are excited to partner with Lillia as we work together to reduce diabetes rates and healthcare costs for over 15,000 QLM members managing the condition. Lillia’s AI-driven health solutions are integral to our mission of transforming healthcare from ‘Illness to Wellness.’ We look forward to further collaboration with them.”
Rajdeep Ghosh, Chief Product and Technology Officer at Dr. Reddy’s Laboratories, also expressed confidence in Lillia’s approach: “Lillia’s diabetes solution integrates technology with an expert-driven behavior change model, which is essential for achieving optimal care outcomes in managing chronic conditions. As Lillia evolves into an AI-first, adaptive care solution provider, we’re eager to see how they leverage AI to further transform the management of chronic diseases.”
The impact of Lillia’s platform is being felt across the healthcare sector. Dr. Akshay Batra, Vice Chairman and MD of Dr. Batra’s Healthcare, praised the company’s contributions: “Lillia has provided a strong technology platform, health experts, and effective patient processes, enabling us to create evidence-based interventions for diabetes and weight management. We’ve seen stellar clinical results for over 1,000 patients across 200+ nationwide clinics. As Lillia continues to push the boundaries of what technology and AI can achieve for health, we’re excited to deepen our clinical impact together.”
As Lillia continues to innovate in the field of chronic disease management, it remains committed to its mission of improving health outcomes through personalized care, advanced AI technology, and strategic partnerships across the healthcare ecosystem. With its expanding reach and growing impact, Lillia is positioning itself as a global leader in AI-driven healthcare solutions.
